Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ)

About JAZZ

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the trea…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

2,890

Website

www.jazzpharma.com/

Fundamentals

1-day range

$244.49$250.64

Market cap

$15.80B

P/E (trailing)

16.97

P/E (forward)

9.47

EPS (trailing)

$14.63

Dividend yield

—

Beta

0.36

Avg. volume

912.6K

Forecasts

20 analyst ratings

Jazz Pharmaceuticals plc Common Stock (Ireland) Competitors

Chosen by industry and closest market cap.

• JAZZ

  Jazz Pharmaceuticals plc Common Stock (Ireland)

  $244.6

  ▼ 2.59%
  Market cap $15.80BP/E 16.97
  $123.88$266.38
• BBIO

  BridgeBio Pharma Inc. Common Stock

  $76.62

  ▼ 2.62%
  Market cap $15.65BP/E —
  $48.78$93.42
• ASND

  Ascendis Pharma A/S Ordinary Share

  $248.06

  ▼ 0.52%
  Market cap $15.09BP/E 26.94
  $186.05$282.15
• ELAN

  Elanco Animal Health Incorporated Common Stock

  $24.12

  ▼ 1.51%
  Market cap $12.85BP/E —
  $17.11$27.98
• MDGL

  Madrigal Pharmaceuticals Inc. Common Stock

  $534.12

  ▼ 1.76%
  Market cap $11.14BP/E —
  $393.61$615
• VTRS

  Viatris Inc. Common Stock

  $16.34

  ▼ 3.26%
  Market cap $20.53BP/E —
  $9.43$18.39
• AXSM

  Axsome Therapeutics Inc. Common Stock

  $199.01

  ▼ 3.52%
  Market cap $10.86BP/E —
  $112.9$260.19

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
  benzinga · 8/25/2026
• 3 Profitable Stocks with Questionable Fundamentals
  Yahoo · 8/16/2026
• Jazz Pharma buys the only shot at a disease with no FDA treatment
  Yahoo · 8/12/2026
• Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
  SeekingAlpha · 8/12/2026
• Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Opportunity
  ChartMill · 8/12/2026
• 5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call
  Yahoo · 8/11/2026
• Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
  Yahoo · 8/11/2026
• Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says
  Yahoo · 8/11/2026
• Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $283
  Benzinga · 8/11/2026

• Patrick Kennedy · August 5, 2026 · Grant

  1.6K
• Samantha Pearce · August 5, 2026 · Tax Withholding

  780 @ $261.62
• Mark Douglas Smith · August 5, 2026 · Grant

  1.6K
• Jennifer E. Cook · August 5, 2026 · Grant

  1.6K
• Laura Hamill · August 5, 2026 · Grant

  1.6K
• Heather Ann McSharry · August 5, 2026 · Grant

  1.6K
• Seamus Mulligan · August 5, 2026 · Grant

  1.6K
• Rick E. Winningham · August 5, 2026 · Grant

  1.6K
• Patrick G. Enright · August 5, 2026 · Grant

  1.6K
• Bruce C. Cozadd · August 5, 2026 · Grant

  1.6K
• Ted W. Love · August 5, 2026 · Grant

  1.6K
• Norbert G. Riedel · August 5, 2026 · Grant

  1.6K
• Bruce C. Cozadd · August 3, 2026 · Sale

  6.0K @ $252.98
• Bruce C. Cozadd · July 1, 2026 · Sale

  6.0K @ $240.47
• Philip L. Johnson · June 30, 2026 · Tax Withholding

  3.3K @ $237.72